Pancreatic Exosomes

Overview

Parent Cell: Akira Pancreatic Beta Cells differentiated from UCT-WJ-MSCs | Pancreatic growth factors and miRNAs for pancreatic beta cell repair and regeneration

Related: Exosomes Overview • Pancreatic Cells

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

The Akira Pancreatic Exosome Matrix is harvested from pancreatic beta-like cells produced through a multi-stage differentiation protocol mimicking pancreatic endocrine development: definitive endoderm induction (Activin-A/Wnt3a), pancreatic progenitor specification (FGF10/Noggin/EGF), and terminal beta cell maturation (Betacellulin/IGF-1/nicotinamide). The resulting cells express PDX1, Nkx6.1, and insulin with glucose-stimulated insulin secretion (GSIS) capacity.

Pancreatic beta cell-derived exosomes carry a highly specialized cargo: miR-375 is the defining beta cell miRNA, regulating glucose homeostasis and insulin secretion. miR-7 suppresses the mTOR pathway in beta cells while also inhibiting NLRP3 in immune cells, providing both beta cell-intrinsic regulation and immune protection of residual islet mass. The secretome delivers EGF, HGF, and Betacellulin — all established beta cell survival and regeneration factors.

Mechanism of Action

Beta Cell Survival & Protection: IGF-1 and EGF cargo activate PI3K/Akt survival signaling in beta cells, protecting against cytokine-induced apoptosis (IL-1β, TNF-α, IFN-γ) — the primary mechanism of beta cell destruction in Type 1 diabetes;^[1] MSC-derived exosomes have been shown to preserve islet survival and insulin secretion function directly.^[2] HGF via Met receptor provides additional anti-apoptotic protection and promotes beta cell proliferation, preserving beta cell mass and mitigating hyperglycemia in diabetic models.^{[3] [4]}

Immune Tolerance Induction: miR-146a suppresses NF-κB in pancreatic-infiltrating macrophages and T cells, reducing islet inflammation — consistent with the broader NF-κB-microRNA regulatory network tuning macrophage inflammatory responses.^[5] IL-10 and TGF-β1 from the secretome promote regulatory T cell (Treg) expansion around residual islet mass. miR-7 inhibits NLRP3 inflammasome activation, blocking IL-1β — a key cytokine in both T1DM and T2DM islet destruction.

Beta Cell Regeneration & Neogenesis: Betacellulin, shown to induce beta cell proliferation and regeneration via ErbB-1/ErbB-2 receptor activation,^[6] and EGF drive proliferation of ductal progenitor cells and transdifferentiation toward beta-like cells. HGF promotes endocrine progenitor expansion. miR-375 — the defining beta-cell-abundant miRNA with multiple roles in endocrine beta cell function^[7] — delivers beta cell identity signals that promote maintenance of the beta cell gene expression program in residual and regenerating islet cells.

Insulin Sensitivity & Glucose Metabolism: GLP-1-associated secretome factors and IGF-1 improve peripheral insulin sensitivity and hepatic glucose uptake independently of beta cell function. This dual mechanism — islet protection combined with peripheral insulin sensitization — addresses both the secretory defect and the insulin resistance components of Type 2 diabetes.

Key Molecular Cargo

Potential Applications

• Type 1 Diabetes Research: islet immune protection mechanisms associated with miR-146a/IL-10; beta cell survival via IGF-1/HGF.
• Type 2 Diabetes Research: beta cell regeneration via Betacellulin/EGF; potential peripheral insulin sensitization.
• Islet Transplantation Support: anti-inflammatory and anti-apoptotic protection of transplanted islets, consistent with MSC/exosome small-RNA immunomodulation of islet transplantation.^[8]
• Pancreatitis Recovery: HGF and EGF are implicated in acinar cell recovery, building on GI growth-factor/hormone signaling described in pancreatic acinar cells;^[9] ductal cell recovery is extrapolated from the same signaling.
• Beta Cell Mass Preservation: IGF-1 cargo, together with EGF-family (Betacellulin) signaling, protects residual beta cell mass during disease progression.
• Metabolic Syndrome Research: insulin sensitivity improvement via IGF-1 and other secretome factors.
• MODY & Genetic Diabetes: beta cell identity maintenance mechanisms (miR-375 and PDX1-associated cargo) relevant to monogenic diabetes research contexts.
• Post-Pancreatectomy Recovery: beta cell neogenesis support proposed via Betacellulin and EGF.

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

The evidence base for this exosome preparation is preclinical and mechanistic rather than product-specific clinical trial data — the beta-cell-lineage cargo (insulin-related miRNAs, beta-cell regulatory molecules) is characterized in vitro and in animal models of islet stress and autoimmune attack, within a broader landscape of stem-cell-based clinical trials for diabetes mellitus.^[10] For product-specific clinical trial data, see the Pancreatic Cells guide, which covers trial results from the parent whole-cell lineage (including a T1DM randomized controlled trial showing 40.7% clinical remission^[11] and an ongoing Phase II/III trial in Type 2 Diabetes^[12]).